SWX:IDIA

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. More Details


Snowflake Analysis

Adequate balance sheet with limited growth.

Share Price & News

How has Idorsia's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: IDIA is not significantly more volatile than the rest of Swiss stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: IDIA's weekly volatility (4%) has been stable over the past year.


Market Performance


7 Day Return

4.2%

IDIA

3.6%

CH Biotechs

0.4%

CH Market


1 Year Return

-15.9%

IDIA

1.3%

CH Biotechs

-0.4%

CH Market

Return vs Industry: IDIA underperformed the Swiss Biotechs industry which returned 1.3% over the past year.

Return vs Market: IDIA underperformed the Swiss Market which returned -0.4% over the past year.


Shareholder returns

IDIAIndustryMarket
7 Day4.2%3.6%0.4%
30 Day8.9%1.5%2.8%
90 Day19.0%2.0%5.8%
1 Year-14.7%-15.9%2.6%1.3%3.1%-0.4%
3 Year-5.1%-6.4%4.3%1.9%19.8%4.7%
5 Yearn/a71.8%66.0%51.9%26.8%

Long-Term Price Volatility Vs. Market

How volatile is Idorsia's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Idorsia undervalued compared to its fair value and its price relative to the market?

18.67x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate IDIA's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate IDIA's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: IDIA is unprofitable, so we can't compare its PE Ratio to the XE Biotechs industry average.

PE vs Market: IDIA is unprofitable, so we can't compare its PE Ratio to the Swiss market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate IDIA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: IDIA is overvalued based on its PB Ratio (18.7x) compared to the CH Biotechs industry average (3x).


Next Steps

Future Growth

How is Idorsia forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

25.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: IDIA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: IDIA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: IDIA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: IDIA's revenue (44.8% per year) is forecast to grow faster than the Swiss market (4.6% per year).

High Growth Revenue: IDIA's revenue (44.8% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: IDIA is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Idorsia performed over the past 5 years?

-26.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: IDIA is currently unprofitable.

Growing Profit Margin: IDIA is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: IDIA is unprofitable, and losses have increased over the past 5 years at a rate of 26.5% per year.

Accelerating Growth: Unable to compare IDIA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IDIA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (7.3%).


Return on Equity

High ROE: IDIA has a negative Return on Equity (-214.38%), as it is currently unprofitable.


Next Steps

Financial Health

How is Idorsia's financial position?


Financial Position Analysis

Short Term Liabilities: IDIA's short term assets (CHF838.2M) exceed its short term liabilities (CHF128.7M).

Long Term Liabilities: IDIA's short term assets (CHF838.2M) exceed its long term liabilities (CHF710.2M).


Debt to Equity History and Analysis

Debt Level: IDIA's debt to equity ratio (278.7%) is considered high.

Reducing Debt: Insufficient data to determine if IDIA's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: IDIA has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: IDIA has sufficient cash runway for 1.8 years if free cash flow continues to reduce at historical rates of 36% each year.


Next Steps

Dividend

What is Idorsia current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate IDIA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate IDIA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if IDIA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IDIA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of IDIA's dividend in 3 years as they are not forecast to pay a notable one for the Swiss market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.7yrs

Average board tenure


CEO

Jean-Paul Clozel (65 yo)

no data

Tenure

Mr. Jean-Paul Clozel, M.D., co- founded Actelion Ltd (alternate name Actelion AG ) in 1997 and has been its Chief Executive Officer since 1999. Mr. Clozel serves as the Chief Executive Officer of Idorsia L...


Board Members

NamePositionTenureCompensationOwnership
Jean-Paul Clozel
CEO & Directorno datano data16.52%
CHF 755.7m
Joern Aldag
Director0.67yrno datano data
Michel de Rosen
Director0.67yrno datano data
Felix Ehrat
Director0.67yrno datano data
Mathieu Simon
Non-Executive Chairmanno datano data0.0051%
CHF 231.5k
Sandesh Mahatme
Director0.67yrno datano data
Viviane Monges
Director2.75yrsno data0.0053%
CHF 241.6k

0.7yrs

Average Tenure

63yo

Average Age

Experienced Board: IDIA's board of directors are not considered experienced ( 0.7 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 26.9%.


Top Shareholders

Company Information

Idorsia Ltd's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Idorsia Ltd
  • Ticker: IDIA
  • Exchange: SWX
  • Founded: 2017
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CHF4.575b
  • Shares outstanding: 166.48m
  • Website: https://www.idorsia.com

Number of Employees


Location

  • Idorsia Ltd
  • Hegenheimermattweg 91
  • Allschwil
  • Basel-Landschaft
  • 4123
  • Switzerland

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
IDIASWX (SIX Swiss Exchange)YesCommon SharesCHCHFJun 2017
0RQELSE (London Stock Exchange)YesCommon SharesGBCHFJun 2017
19TDB (Deutsche Boerse AG)YesCommon SharesDEEURJun 2017
IDRS.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDJun 2017

Biography

Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeuti...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/01/16 18:09
End of Day Share Price2021/01/15 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.